Scientists seek antimycobacterial drugs to tackle MTB
MTB research carried out by scientists

HPLC, UHPLC

Scientists seek antimycobacterial drugs to tackle MTB

13 Apr, 2011

Published over 15 years ago. See the latest and most current information on HPLC, UHPLC.

Scientists have sought antimycobacterial drugs in medicinal plants in order to tackle Mycobacterium tuberculosis (MTB).

Published in BMC Complementary and Alternative Medicine, the paper explains that tuberculosis (TB) is caused by MTB.

The latter's resistance to antibacterial drugs is a "public health concern", the researchers highlight.

As such, they analysed the antimycobacterial activity of n-Hexane sub-fraction from Bridelia micrantha.

Resistant to all first-line drugs which tackle TB, a clinical isolate was used to test the effectiveness of the n-Hexane fraction.

It was found to inhibit it by 35 per cent, while tests against a strain of MTB were 20 per cent inhibited.

Chromatography and a variety of other techniques were used in order to acquire the data.

"The results show that the n-Hexane fraction of Bridelia micrantha has antimycobacterial activity," conclude the scientists Ezekiel Green, Lawrence Obi, Amidou Samie, Pascal Bessong and Roland Ndip.

BMC Complementary and Alternative Medicine is an open-access online journal, which publishes peer-reviewed papers focusing on scientific research in this area.
 

Latest News

Explore Our Other Sites

Labmate Online
Lab-grown kidney organoids set to recast research landscape into kidney disease
Explore more Arrow
Envirotech Online
EU ETS benchmark update puts industrial emissions data under sharper scrutiny
Explore more Arrow
Pollution Solutions Online
Next-generation reverse osmosis membranes for more efficient and cost-effective seawater desalination
Explore more Arrow
Petro Online
New test method ASTM D8606 has been officially released
Explore more Arrow